Related Experiment Video
Updated: Aug 16, 2026
![An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F66708.jpg&w=3840&q=50)
An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use
Published on: May 24, 2024
Farnesyl transferase inhibitors: current developments and future perspectives
F A Eskens1, G Stoter, J Verweij
1Department of Medical Oncology, Rotterdam Cancer Institute (Daniel den Hoed Kliniek), Rotterdam, The Netherlands. eskens@oncd.azr.nl
Abstract:
Ras oncogenes play an important role in carcinogenesis and are frequently found in various human tumour types. Cellular activity of Ras oncoprotein, regulated through the enzyme farnesyl transferase, is crucial in the process of ras -dependent carcinogenesis, and therefore, specific inhibition of this enzyme is an attractive goal in anticancer treatment. Specific inhibitors of farnesyl transferase have been developed in recent years, many of them showing in vitro and in vivo growth inhibitory or cytostatic activity. Recently, results of the first clinical studies with various farnesyl transferase inhibitors have been presented. In the design of phase I and II studies, either single-agent or combination studies, new endpoints have to be defined in order to properly assess feasibility, antitumour activity and clinical valuability.
Insights
Ras oncogene inhibition is a promising anticancer strategy. Farnesyl transferase inhibitors show potential, with early clinical studies defining new endpoints for treatment assessment.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Ras oncogenes are critical drivers of human carcinogenesis.
- Ras oncoprotein activity, regulated by farnesyl transferase, is essential for tumor development.
- Targeting farnesyl transferase is a key strategy in anticancer drug development.
Purpose of the Study:
- To review the role of Ras oncogenes in cancer.
- To discuss the development and therapeutic potential of farnesyl transferase inhibitors.
- To highlight the need for new endpoints in clinical trials for these agents.
Main Methods:
- Review of preclinical and clinical data on farnesyl transferase inhibitors.
- Analysis of the mechanism of Ras-dependent carcinogenesis.
- Evaluation of emerging clinical trial designs and endpoints.
Main Results:
- Farnesyl transferase inhibitors demonstrate significant in vitro and in vivo antitumor activity.
- Early clinical studies with these inhibitors are underway.
- New endpoints are required to accurately assess clinical value.
Conclusions:
- Farnesyl transferase inhibitors represent a promising therapeutic avenue for Ras-driven cancers.
- Further clinical investigation is necessary to establish their efficacy and optimal use.
- Defining appropriate endpoints is crucial for successful clinical development.
More Related Videos
10:29Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
10:33Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment
Published on: April 25, 2025
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Pharmacogenomics: Identification of New Drug Targets
Inhibitors of Viral Protein Synthesis